$0.68
6.91% yesterday
Nasdaq, Nov 15, 09:50 pm CET
ISIN
US2936021086
Symbol
ENSC
Sector
Industry

Ensysce Biosciences Inc Stock price

$0.67
+0.50 298.10% 1M
+0.06 9.52% 6M
-0.39 36.75% YTD
-0.21 24.00% 1Y
-512.93 99.87% 3Y
-2,466.53 99.97% 5Y
-2,315.33 99.97% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.03 5.46%
ISIN
US2936021086
Symbol
ENSC
Sector
Industry

Key metrics

Market capitalization $9.48m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 2.14
P/B ratio (TTM) P/B ratio 2.87
Revenue growth (TTM) Revenue growth 40.41%
Revenue (TTM) Revenue $4.42m
EBIT (operating result TTM) EBIT $-6.31m
Cash position $4.15m
EPS (TTM) EPS $-1.82
P/S forward 2.20
Short interest 45.08%
Show more

Is Ensysce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Ensysce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Ensysce Biosciences Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Ensysce Biosciences Inc:

Buy
100%

Financial data from Ensysce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.42 4.42
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.08 5.08
-
115%
- Research and Development Expense 5.65 5.65
-
128%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.31 -6.31
-
-143%
Net Profit -7.93 -7.93
-
-179%

In millions USD.

Don't miss a Thing! We will send you all news about Ensysce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ensysce Biosciences Inc Stock News

Neutral
Accesswire
3 days ago
Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWIRE / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while r...
Neutral
Accesswire
9 days ago
SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice from The Nasdaq Stock Market ("Nasdaq") as described in a decision dated November 5,...
Neutral
Accesswire
about one month ago
~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~ ~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid ...
More Ensysce Biosciences Inc News

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.

Head office United States
CEO D. Kirkpatrick
Employees 9
Founded 2003
Website www.ensysce.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today